These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379 [TBL] [Abstract][Full Text] [Related]
3. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Allanore Y; Borderie D; Meune C; Cabanes L; Weber S; Ekindjian OG; Kahan A Arthritis Rheum; 2003 Dec; 48(12):3503-8. PubMed ID: 14674001 [TBL] [Abstract][Full Text] [Related]
4. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of exercise pulmonary arterial hypertension in scleroderma. Callejas-Rubio JL; Moreno-Escobar E; de la Fuente PM; Pérez LL; Fernández RR; Sánchez-Cano D; Mora JP; Ortego-Centeno N J Rheumatol; 2008 Sep; 35(9):1812-6. PubMed ID: 18634147 [TBL] [Abstract][Full Text] [Related]
6. [Seven years of experience in patients with pulmonary arterial hypertension in Ege University Hospital: diagnostic approach of a single center]. Kayikçioğlu M; Kültürsay H Anadolu Kardiyol Derg; 2008 Aug; 8(4):279-85. PubMed ID: 18676304 [TBL] [Abstract][Full Text] [Related]
7. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Distler O; Behrens F; Pittrow D; Huscher D; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Furst DE; Arthritis Rheum; 2008 Jun; 59(6):867-75. PubMed ID: 18512721 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand. Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025 [TBL] [Abstract][Full Text] [Related]
9. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Hofstee HM; Vonk Noordegraaf A; Voskuyl AE; Dijkmans BA; Postmus PE; Smulders YM; Serné EH Ann Rheum Dis; 2009 Feb; 68(2):191-5. PubMed ID: 18375538 [TBL] [Abstract][Full Text] [Related]
13. Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al. Dimitroulas T; Giannakoulas G; Karvounis H; Settas L Arthritis Rheum; 2008 Jul; 58(7):2215-6; author reply 2216. PubMed ID: 18576342 [No Abstract] [Full Text] [Related]
14. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Proudman SM; Stevens WM; Sahhar J; Celermajer D Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726 [TBL] [Abstract][Full Text] [Related]
15. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Carulli MT; Handler C; Coghlan JG; Black CM; Denton CP Ann Rheum Dis; 2008 Jan; 67(1):105-9. PubMed ID: 17604287 [TBL] [Abstract][Full Text] [Related]
16. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? Vancheeswaran R; Magoulas T; Efrat G; Wheeler-Jones C; Olsen I; Penny R; Black CM J Rheumatol; 1994 Oct; 21(10):1838-44. PubMed ID: 7837147 [TBL] [Abstract][Full Text] [Related]
17. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Hachulla E; de Groote P; Gressin V; Sibilia J; Diot E; Carpentier P; Mouthon L; Hatron PY; Jego P; Allanore Y; Tiev KP; Agard C; Cosnes A; Cirstea D; Constans J; Farge D; Viallard JF; Harle JR; Patat F; Imbert B; Kahan A; Cabane J; Clerson P; Guillevin L; Humbert M; Arthritis Rheum; 2009 Jun; 60(6):1831-9. PubMed ID: 19479881 [TBL] [Abstract][Full Text] [Related]
18. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686 [TBL] [Abstract][Full Text] [Related]